ERSEUS 1996, Perseus’ first fund, was formed in 1996 with $35 million in capital commitments to invest in small buyout, growth equity, and venture capital transactions.

PERSEUS CAPITAL, L.L.C. was formed in 1997 with $102 million in capital commitments to focus on growth equity and small buyout opportunities.

PERSEUS ACQUISITION/RECAPITALIZATION FUND, L.L.C. was formed in 1999 with $432 million in capital commitments to make substantial investments (greater than $25 million) in leveraged acquisitions and recapitalizations of operating companies alongside other Perseus funds.

PERSEUS 2000, L.L.C. was formed in 2000 with $222 million in capital commitments to invest in mid- and late-stage, industry-specific opportunities.

PERSEUS 2000 EXPANSION, L.L.C. which was formed in 2004, is a $153 million fund used for follow-on investments for the Perseus 2000 fund and other small buyout and growth equity transactions.

PERSEUS MARKET OPPORTUNITY FUND, L.P. closed in 2004 with $340 million of committed capital to pursue growth equity and buyout investments with a particular emphasis on transactions involving publicly traded companies.

PERSEUS PARTNERS VII, L.P., established in 2006, is a $600 million fund focused on middle market buyout and growth equity transactions in the following three investment areas: undervalued public companies and distressed investments; biotechnology and medical device consolidations; and energy, environmental and engineering technology investments.

PERSEUS-SOROS BIOPHARMACEUTICAL FUND, L.P., which Perseus co-manages, was formed in 2000 with capital commitments totaling $449 million to make investments in life sciences companies